Table 3.
The relationship between clinical, biochemical, and hormonal parameters and leptin serum concentration in Hashimoto thyroiditis patients and the control group.
| Control group (n = 46) | Hashimoto thyroiditis (n = 39) | |
|---|---|---|
| Leptin | ||
| Age (years) | r=-0.17, p=0.35 | r=-0.17, p=0.35 |
| BMI (kg/m2) | r=0.75, p<0.01 | r=0.75, p<0.01 |
| % body fat | r=0.80, p<0.01 | r=0.73, p<0.01 |
| Android fat mass (kg) | r=0.77, p=<0.01 | r=0.87, p<0.01 |
| Gynoid fat mass (kg) | r=0.82, p=<0.01 | r=0.82, p<0.01 |
| VAT (g) | r=0.61, p=<0.01 | r=0.64, p<0.01 |
| TSH (uIU/ml) | r=-0.01, p=0.93 | r=-0.01, p=0.93 |
| fT4 (ng/dl) | r=-0.6, p=0.74 | r=0.24, p=0.19 |
| fT3 (pg/ml) | r=-0.1, p=0.92 | r=-0.1, p=0.97 |
| TPOAbs (IU/ml) | r=-0.01, p=0.73 | r=-0.01, p=0.92 |
| TgAbs (IU/ml) | r=0.3, p=0.17 | r=0.3, p=0.17 |
Data are derived from Spearman correlation coefficient. The level of significance was accepted at p < 0.05.
BMI, body mass index; VAT, visceral adipose tissue; TSH, thyroid−stimulating hormone; fT4, free T4; fT3, free T3; TPOAbs, thyroid peroxidase antibodies; TgAbs, antibodies against thyroglobulin.